ARS Pharmaceuticals Inc (SPRY) Stock AnalysisSPRYStock AnalysisARS Pharmaceuticals Inc

ARS Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. It is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

ARS Pharmaceuticals Inc is currently trading at $5.89, significantly below analyst price targets of $25 and $30, indicating potential upside. However, the company has a troubling net income of -$62.34 million for Q2 2026 and faces class action lawsuits, which pose risks. The RSI is at 51.14, suggesting the stock is neither overbought nor oversold, but the recent 23% drop due to insurance coverage issues raises concerns about market confidence. Therefore, while there is potential for growth, the risks are substantial, warranting a hold position for now.